Pomalidomide
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Pomalidomide
Description:
Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.Product Name Alternative:
CC-4047UNSPSC:
12352005Hazard Statement:
H360Target:
Apoptosis; Ligands for E3 Ligase; Molecular GluesType:
Reference compoundRelated Pathways:
Apoptosis; PROTACApplications:
Cancer-programmed cell deathField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/Pomalidomide.htmlPurity:
99.96Solubility:
DMSO : 50 mg/mL (ultrasonic)Smiles:
O=C1N (C (C2=C1C=CC=C2N) =O) C (C (N3) =O) CCC3=OMolecular Formula:
C13H11N3O4Molecular Weight:
273.24Precautions:
H360References & Citations:
[1]Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54 (4) :683-7.|[2]Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11 (16) :5984-92.|[3]Schafer PH, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 Jun;305 (3) :1222-32.|[4]Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8 (8) :e71754.|[5]Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22 (6) :755-63.|[6]Liu D, et al. Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.) . Gen Comp Endocrinol. 2016 Mar 1;228:1-8.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
LaunchedIsoform:
CereblonCAS Number:
19171-19-8
